Log in

NYSEAMERICAN:PTN - Palatin Technologies Stock Price, Forecast & News

$0.43
-0.04 (-8.54 %)
(As of 03/27/2020 04:00 PM ET)
Today's Range
$0.43
Now: $0.43
$0.47
50-Day Range
$0.87
MA: $0.93
$1.06
52-Week Range
$0.36
Now: $0.43
$1.78
Volume922,920 shs
Average Volume1.57 million shs
Market Capitalization$98.21 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific therapeutics for the treatment of various diseases in the United States. The company's principal product is Vyleesi, an on demand subcutaneous injectable product that has completed Phase III clinical studies for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. Its drug development programs also include melanocortin receptor system program, such as PL-8177, a selective melanocortin receptor 1 agonist peptide for inflammatory bowel diseases; and PL-8331, a preclinical development candidate for treating ocular inflammation, as well as melanocortin receptor 4 peptides and orally-active small molecules to treat genetic metabolic and obesity disorders. In addition, the company develops natriuretic peptide receptor systems comprising PL­3994, a natriuretic peptide receptor-A agonist, which has completed Phase I clinical study for the treatment of cardiovascular indications; and PL-5028, a dual natriuretic peptide receptor A and C agonist that is in preclinical development for cardiovascular diseases, such as reducing cardiac hypertrophy and fibrosis. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.
Read More
Palatin Technologies logo

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:PTN
CUSIPN/A
Phone+1-609-4952200

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees19
Market Cap$98.21 million
Next Earnings Date5/14/2020 (Estimated)
OptionableNot Optionable

Receive PTN News and Ratings via Email

Sign-up to receive the latest news and ratings for PTN and its competitors with MarketBeat's FREE daily newsletter.


Palatin Technologies (NYSEAMERICAN:PTN) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Palatin Technologies?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Palatin Technologies in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Palatin Technologies.

When is Palatin Technologies' next earnings date?

Palatin Technologies is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Palatin Technologies.

How were Palatin Technologies' earnings last quarter?

Palatin Technologies, Inc. (NYSEAMERICAN:PTN) issued its earnings results on Tuesday, February, 11th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.01) by $0.01. The biopharmaceutical company earned $0.02 million during the quarter, compared to analyst estimates of $4.48 million. During the same period in the prior year, the firm posted ($0.02) EPS. View Palatin Technologies' earnings history.

What price target have analysts set for PTN?

3 Wall Street analysts have issued 1 year target prices for Palatin Technologies' stock. Their forecasts range from $2.00 to $6.00. On average, they expect Palatin Technologies' stock price to reach $3.67 in the next twelve months. This suggests a possible upside of 755.9% from the stock's current price. View analysts' price targets for Palatin Technologies.

Has Palatin Technologies been receiving favorable news coverage?

Media headlines about PTN stock have been trending positive on Saturday, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Palatin Technologies earned a news sentiment score of 2.1 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the next several days. View the latest news aboutPalatin Technologies.

Are investors shorting Palatin Technologies?

Palatin Technologies saw a decline in short interest in February. As of February 14th, there was short interest totaling 22,300,000 shares, a decline of 7.5% from the January 30th total of 24,110,000 shares. Based on an average trading volume of 1,130,000 shares, the days-to-cover ratio is presently 19.7 days. Approximately 11.2% of the shares of the stock are sold short. View Palatin Technologies' Current Options Chain.

Who are some of Palatin Technologies' key competitors?

What other stocks do shareholders of Palatin Technologies own?

Who are Palatin Technologies' key executives?

Palatin Technologies' management team includes the following people:
  • Dr. John K. A. Prendergast, Co-Founder & Non-Exec. Chairman (Age 65)
  • Dr. Carl Spana, Co-Founder, Pres, CEO & Director (Age 57)
  • Mr. Stephen T. Wills CPA, CPA, MST, CFO, COO, Exec. VP, Treasurer & Sec. (Age 62)
  • Burns McClellan, VP of Investor Relations

What is Palatin Technologies' stock symbol?

Palatin Technologies trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PTN."

Who are Palatin Technologies' major shareholders?

Palatin Technologies' stock is owned by a variety of institutional and retail investors. Top institutional investors include State Street Corp (1.55%), Acadian Asset Management LLC (1.42%), Geode Capital Management LLC (1.19%), Strs Ohio (0.34%), AQR Capital Management LLC (0.32%) and Bank of New York Mellon Corp (0.24%). Company insiders that own Palatin Technologies stock include Alan W Dunton, Arlene Morris, Carl Spana, Joseph Stanley Hull, Robert K Deveer Jr and Stephen T Wills. View institutional ownership trends for Palatin Technologies.

Which institutional investors are selling Palatin Technologies stock?

PTN stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, New York State Common Retirement Fund, Oxford Asset Management LLP, and California Public Employees Retirement System. View insider buying and selling activity for Palatin Technologies.

Which institutional investors are buying Palatin Technologies stock?

PTN stock was acquired by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Acadian Asset Management LLC, Virtu Financial LLC, Strs Ohio, Geode Capital Management LLC, Banque Cantonale Vaudoise, Barclays PLC, and UBS Group AG. Company insiders that have bought Palatin Technologies stock in the last two years include Alan W Dunton, Arlene Morris, Carl Spana, Joseph Stanley Hull, Robert K Deveer Jr, and Stephen T Wills. View insider buying and selling activity for Palatin Technologies.

How do I buy shares of Palatin Technologies?

Shares of PTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Palatin Technologies' stock price today?

One share of PTN stock can currently be purchased for approximately $0.43.

How big of a company is Palatin Technologies?

Palatin Technologies has a market capitalization of $98.21 million. Palatin Technologies employs 19 workers across the globe. View additional information about Palatin Technologies.

What is Palatin Technologies' official website?

The official website for Palatin Technologies is http://www.palatin.com/.

How can I contact Palatin Technologies?

Palatin Technologies' mailing address is 4B Cedarbrook Dr, CRANBURY, NJ 08512-3641, United States. The biopharmaceutical company can be reached via phone at +1-609-4952200.


MarketBeat Community Rating for Palatin Technologies (NYSEAMERICAN PTN)

Community Ranking:  3.0 out of 5 (star star)
Outperform Votes:  418 (Thanks for Voting!)
Underperform Votes:  290 (Thanks for Voting!)
Total Votes:  708
MarketBeat's community ratings are surveys of what our community members think about Palatin Technologies and other stocks. Vote "Outperform" if you believe PTN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/28/2020 by MarketBeat.com Staff

Featured Article: Market Indexes

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel